Medication info
Antiium Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Antiium Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Kujoo Pharmaceutical Co., Ltd.
Appearance
Pink, round, film-coated tablet
Packaging
28 tablets (14 tablets / PTP X 2)
Approval status
Active

MFDS item code 201404588 · Approved 2014.10.06 · Insurance code 669804480

Summary

Main use
Treatment of reflux and Zollinger-Ellison syndrome; adjunctive therapy for eradication; treatment of gastrointestinal symptoms and ulcers; prevention of rebleeding
Who uses it
Adults · Children
Adult dosage
1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · Adults may take 20 mg once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical studies have been conducted for periods exceeding 4 weeks. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Older adults: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Ingredients

Manufacturer
Kujoo Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of reflux and Zollinger-Ellison syndrome; adjunctive therapy for eradication; treatment of gastrointestinal symptoms and ulcers; prevention of rebleeding

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcers
  • duodenal ulcers
View approved original text

This medication treats gastroesophageal reflux disease (GERD) and erosive reflux esophagitis, and is also used for long-term maintenance therapy to prevent recurrence in patients with esophagitis. Additionally, it is effective in alleviating symptoms in patients with gastroesophageal reflux disease without esophagitis. It is used in combination with antibiotics for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers caused by Helicobacter pylori infection. It short-term treats upper gastrointestinal symptoms (pain, discomfort, burning sensation) due to the intake of non-steroidal anti-inflammatory drugs and helps treat and prevent gastric ulcers and duodenal ulcers that may occur during continuous non-steroidal anti-inflammatory drug intake. Moreover, it is used for the treatment of Zollinger-Ellison syndrome and for maintenance therapy after preventing rebleeding of gastric or duodenal ulcers. It is effectively used in the treatment and prevention of various gastrointestinal diseases.

Dosage and Administration

Adult dosage

1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · Adults may take 20 mg once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of gastric and duodenal ulcers due to treatment with nonsteroidal anti-inflammatory drugs. 2) Combination therapy with antibiotics for eradication of Helicobacter pylori Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with administration of nonsteroidal anti-inflammatory drugs (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. No clinical studies have been conducted for periods exceeding 4 weeks. 4) Patients requiring continuous treatment with nonsteroidal anti-inflammatory drugs - Treatment of gastric ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with administration of nonsteroidal anti-inflammatory drugs: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue for as long as clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses exceeding 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding due to gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Older adults: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. Patients whose esophagitis has not healed or whose symptoms persist should take the medicine for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. 3. Children under 12 years of age: There is no experience with administration of this medicine to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. It is contraindicated in patients with hypersensitivity to this medication or its ingredients, or to benzimidazoles, or with a history of such sensitivity. Patients with allergies to penicillins or macrolide antibiotics should not use this medication when combining it with amoxicillin or clarithromycin for the eradication of Helicobacter pylori. Additionally, this medication should not be taken by patients receiving certain heart-related medications or antivirals, nursing mothers, or those with a history of myocardial infarction. Various adverse reactions may occur upon taking this medication. Decreased blood cell counts, hypersensitivity reactions, electrolyte imbalances, neurological symptoms such as headaches or dizziness, gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, and vomiting have been reported. Rarely, severe skin reactions, liver function abnormalities, or muscle problems may occur, requiring caution. Regular check-ups are necessary for long-term use of this medication. Specifically, for those who take it over a year, blood tests including magnesium levels should be conducted to check for abnormalities. Furthermore, if symptoms indicating malignancy are suspected, a specialist consultation should be sought before taking this medication. This medication may interact with other drugs, so it is essential to inform the doctor or pharmacist about any concomitant medications. Care should be taken when combining with drugs that affect blood coagulation, antivirals, or certain antibiotics. The safety of this medication during pregnancy has not been sufficiently established, and it should only be used under medical supervision if deemed necessary. It is recommended not to take this medication while breastfeeding. In the case of overdose, because there is no specific antidote, symptoms should be monitored, and appropriate treatment should be received. This medication should be kept out of reach of children, and it is advisable not to transfer it to another container.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reactions, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, xerostomia, stomatitis, gastrointestinal candidiasis, microscopic colitis, elevated liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, pruritus, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reactions, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, influenza-like illness, generalized edema, leg edema, malaise, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid tumors, colonic hypersensitivity, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, lingual disorders, glossedema, ulcerative stomatitis, earache, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, articular disorders, convulsions, fibromyalgia syndrome, hernia, polymyalgia rheumatica, loss of appetite, apathy, increased appetite, confusion, worsening depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorders, tremor, visual field defect, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal pruritus, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste distortion, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infections, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, discoid lupus erythematosus, gastric polyp, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The recommended storage temperature is between 1°C and 30°C.

Appearance and packaging

Appearance

Pink, round, film-coated tablet

Package unit

28 tablets (14 tablets / PTP X 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.